News, trends, and stories from the synthetic biology industry

Hi all,

The synthetic biology industry’s biggest event of the year is just 20 days away and prices increase at midnight tonight. See below for some of the new sessions just announced.

I promised you some exciting new ways to interact digitally with fellow SynBioBeta members and attendees. And today we’re announcing two exciting opportunities to do that.

Tomorrow, 8am Pacific:
Join myself and Berkeley Lights CEO Eric Hobbs for the SynBioBeta Podcast live recording. We’ll discuss their recent IPO, benchmarking in synthetic biology, and more. It will be followed by the premiere of our virtual networking space shown above. This will be an exclusive event for members of the Bioeconomy Hub, a year-long membership focused on amazing experiences that will connect you with the community, educate you on the industry’s most pressing issues, and provide the tools you need to thrive in this field. Sign up for the Bioeconomy Hub to gain access to this event and many more, including SynBioBeta 2020 and 2021. If you already have a ticket to SynBioBeta and want to upgrade to a membership then drop me a note.

SynBioBeta Poster Session Deadline next Tuesday September 15th:
I welcome you to apply for the SynBioBeta poster to present your work during the conference. If you are a student or postdoc then you can also apply for a discounted ticket here. Attendees will be able to connect with others who have posters on display in our interactive networking environment.

In other SynBioBeta 2020 news, check out these new sessions just announced:

Register now

I recently spoke with Nishan Degnarain for his Forbes column about how Silicon Valley synthetic biology companies have been racing to offer support to the Indian Ocean island famous for its rare biodiversity, Mauritius, due to the recent oil spill.

In funding news:

Synthetic biology startups raised $3.0 billion in the first half of 2020. While COVID-19 slowed the startup economy in the first half of 2020, the bioeconomy continued to power ahead. Coronavirus is not hampering the estimated $4 trillion bioeconomy being driven by synthetic biology.

Could fermentation power the future of plant-based foods? Motif FoodWorks thinks yes. Jon McIntyre, CEO of Motif FoodWorks, shares his company’s strategy for revolutionizing plant-based foods through microbes and fermentation, and his views on the future of food and synthetic biology.

Demetrix is scaling the cannabinoid industry. In the race to find the next great product in the cannabinoid family of chemicals, Berkeley-based Demetrix announced that it has commenced 15,000-liter demo-scale fermentation production of CBG, the first rare cannabinoid it will take to market.

When Covid hit and hospitals started reporting drug shortages, it became clear that our drug supply chain was broken. In a Nature paper, Christina Smolke reports a breakthrough in making plant-based medicines that lays the foundation for a flexible, on-demand drug supply chain.

CAR-T is such a powerful tool against cancer, this is a great 3 min explainer video featuring Precigen and how their technology works against ovarian cancer.

Have a great rest of the week.

COVID-19 News

Latest News

‘CRISPR babies’ are still too risky, says influential panel (Nature News)

Will bacterial ‘wires’ one day power your phone? (Science News)

Earlham Institute’s synthetic biology team rewrites the rules on plant gene expression

CRISPR can help combat the troubling immune response against gene therapy (The Conversation)

Atelerix awarded Innovate UK funding to enable transport and storage of cellular therapies at room temperature (Cambridge Network)

Q&A with the new Managing Director of IndieBio, Po Bronson

District 3 opens state-of-the-art BioHub accelerator at Concordia

BiomX enters collaboration with Boehringer Ingelheim with the goal of discovering microbiome-based biomarkers for inflammatory bowel disease (Press release)

Synthesea is a start-up that aims to develop cheap, sustainable lipid synthesis tools (Imperial College)

A zest for synthetic biology: why are metabolic engineers so interested in limonene? (ASBMB Today)

Evonetix and Analog Devices collaborate on third-generation DNA synthesis platform (Press release)

Who's hiring?

Senior Process Engineer: Inscripta – San Diego, CA

Technical Informatics Specialist (TIS): Inscripta – Boulder, CO

Cell Biology (Microbe): Inscripta – Boulder, CO

PhD Scientist: Procter & Gamble – Cincinnati, Ohio

Data Scientist: Inscripta – Remote Worker

Senior Research Assistant: Colorifix – Norwich Research Park, Norwich

Lead Metabolic Engineering Scientist: Helaina – New York, NY

Synthetic Chemist: Elegen – San Carlos, CA

Fluidics Engineer: Elegen – San Carlos, CA

Senior Synthetic Biologist: Elegen – San Carlos, CA

Senior Scientist/Engineer (Mammalian Cell Process Development): Artemys Foods – San Leandro, CA

Scientist/Engineer (Scale down process development): Artemys Foods – San Leandro, CA

Research Associate: LanzaTech – Skokie, IL

System Integration Scientist: Inscripta – Pleasanton, CA

Senior Instrument Control Software Engineer: Inscripta – Pleasanton, CA

Field Service Engineer (FSE): Inscripta – Europe

Account Executive: Inscripta – Midwest, US

Staff Scientist (Enzyme Engineering): Inscripta – Pleasanton, CA

Scientist, Enzyme Engineering: Inscripta – Pleasanton, CA

Scientist, Analytical Chemistry (Physical Properties & Characterization): Geltor – San Leandro, CA

Senior Scientist, Analytical Chemistry: Geltor – San Leandro, CA

Scientist, Mammalian Cell Biology: Inscripta – Pleasanton, CA

Technology Development Engineer/Scientist: Inscripta – Boulder, CO

Senior Scientist, Biochemistry: Inscripta – Pleasanton, CA

Computational Biology Scientist: Inscripta – Boulder, CO

Field Applications Scientist – East: Inscripta, Boston, MA

Account Executive: Inscripta – East Coast, United States

Feature your job here